1. Home
  2. CCCC vs ONL Comparison

CCCC vs ONL Comparison

Compare CCCC & ONL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCCC
  • ONL
  • Stock Information
  • Founded
  • CCCC 2015
  • ONL 2021
  • Country
  • CCCC United States
  • ONL United States
  • Employees
  • CCCC N/A
  • ONL N/A
  • Industry
  • CCCC Biotechnology: Pharmaceutical Preparations
  • ONL Real Estate Investment Trusts
  • Sector
  • CCCC Health Care
  • ONL Real Estate
  • Exchange
  • CCCC Nasdaq
  • ONL Nasdaq
  • Market Cap
  • CCCC 104.4M
  • ONL 119.7M
  • IPO Year
  • CCCC 2020
  • ONL N/A
  • Fundamental
  • Price
  • CCCC $2.26
  • ONL $2.73
  • Analyst Decision
  • CCCC Buy
  • ONL Hold
  • Analyst Count
  • CCCC 3
  • ONL 1
  • Target Price
  • CCCC $12.00
  • ONL N/A
  • AVG Volume (30 Days)
  • CCCC 2.0M
  • ONL 896.7K
  • Earning Date
  • CCCC 08-04-2025
  • ONL 08-06-2025
  • Dividend Yield
  • CCCC N/A
  • ONL 2.93%
  • EPS Growth
  • CCCC N/A
  • ONL N/A
  • EPS
  • CCCC N/A
  • ONL N/A
  • Revenue
  • CCCC $39,783,000.00
  • ONL $154,796,000.00
  • Revenue This Year
  • CCCC N/A
  • ONL N/A
  • Revenue Next Year
  • CCCC N/A
  • ONL N/A
  • P/E Ratio
  • CCCC N/A
  • ONL N/A
  • Revenue Growth
  • CCCC 98.56
  • ONL N/A
  • 52 Week Low
  • CCCC $1.09
  • ONL $1.46
  • 52 Week High
  • CCCC $7.36
  • ONL $4.39
  • Technical
  • Relative Strength Index (RSI)
  • CCCC 60.73
  • ONL 70.00
  • Support Level
  • CCCC $2.15
  • ONL $2.54
  • Resistance Level
  • CCCC $2.53
  • ONL $2.77
  • Average True Range (ATR)
  • CCCC 0.28
  • ONL 0.10
  • MACD
  • CCCC 0.02
  • ONL 0.03
  • Stochastic Oscillator
  • CCCC 62.13
  • ONL 91.67

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

About ONL Orion Office REIT Inc.

Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.

Share on Social Networks: